Mecwins is pleased to announce that the Japan Patent Office has granted a new patent for an innovative platform for multiplexed, high-throughput and ultrasensitive optical detection of plasmonic nanoparticle-labeled biomarkers. The patent, entitled “Biosensor platform and method for simultaneous, multiplexed, ultrasensitive and high-throughput optical detection of biomarkers” (Patent JP7515286B2), represents a significant advancement in biosensing technology.
This invention provides a biosensing platform that detects and quantifies biomarkers with exceptional sensitivity by capturing and analyzing spatially and spectrally resolved data from the surface of a biosensor using plasmonic nanoparticles as labels.
The issuance of this patent underscores Mecwins’ commitment to innovation and excellence in nanotechnology and biosensing. This achievement not only enhances our intellectual property portfolio, but also strengthens our position as a primary innovator of technological solutions for the biotechnology sector.
We are proud to share the official patent certificate that marks this milestone in our mission of technological excellence.
